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Abstract
Genome wide association studies have identified single nucleotide polymorphisms (SNP) within fibroblast growth factor
receptor 2 (FGFR2) as one of the highest ranking risk alleles in terms of development of breast cancer. The potential effect of
these SNPs, in intron two, was postulated to be due to the differential binding of cis-regulatory elements, such as
transcription factors, since all the SNPs in linkage disequilibrium were located in a regulatory DNA region. A Runx2 binding
site was reported to be functional only in the minor, disease associated allele of rs2981578, resulting in increased expression
of FGFR2 in cancers from patients homozygous for that allele. Moreover, the increased risk conferred by the minor FGFR2
allele associates most strongly in oestrogen receptor alpha positive (ERa) breast tumours, suggesting a potential interaction
between ERa and FGFR signalling. Here, we have developed a human cell line model system to study the effect of the
putative functional SNP, rs2981578, on cell behaviour. MCF7 cells, an ERa positive breast cancer cell line homozygous for the
wild-type allele were edited using a Zinc Finger Nuclease approach. Unexpectedly, the acquisition of a single risk allele in
MCF7 clones failed to affect proliferation or cell cycle progression. Binding of Runx2 to the risk allele was not observed.
However FOXA1 binding, an important ERa partner, appeared decreased at the rs2981578 locus in the risk allele cells.
Differences in allele specific expression (ASE) of FGFR2 were not observed in a panel of 72 ERa positive breast cancer
samples. Thus, the apparent increased risk of developing ERa positive breast cancer seems not to be caused by rs2981578
alone. Rather, the observed increased risk of developing breast cancer might be the result of a coordinated effect of
multiple SNPs forming a risk haplotype in the second intron of FGFR2.
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Introduction
Breast cancer is the most common malignancy among women,
with an estimated 1 million new cases and over 400,000 deaths
annually worldwide [1]. The development of breast cancers, in the
absence of high penetrance susceptibility genes like BRCA1 and
BRCA2, is caused by a multitude of genetic factors, each conferring
a small increase in the overall risk, and various environmental
factors [2]. Genome wide association studies (GWAS) have
successfully identified many risk loci linked with susceptibility to
altered response to drug treatment and other phenotypic
variations. Particularly, an haplotype of SNPs located in the
second intron of the Fibroblast growth factor receptor 2 (FGFR2) gene
has been linked to increased risk of ER positive breast cancer. This
was one of the top five significant loci identified by early GWAS
[3,4], with an homozygous risk allele frequency of approximately
28% in the European population (ENSEMBL). However the
connection between most of those variants, including the FGFR2
haplotype, and the underlying mechanism of carcinogenesis
remains unknown. Comprehensive functional validation studies
are needed to better understand the biological significance of these
risk alleles.
An early functional study on the FGFR2 SNPs hypothesised that
rs2981578 was the functional element of the risk haplotype, and
that allele specific expression of FGFR2 was mediated by
differential binding of the trans-acting enhancer by the Runx2/
Oct1 complex [5]. Since FGFR signalling, and FGFR2 in
particular, has been implicated as a driving force in breast cancer
[6], over-expression of FGFR2 as a result of such alterations in
transcriptional regulation was postulated as the underlying cause
of the increased risk of developing breast cancer.
Given the vast genetic differences that exist between breast
cancer cell lines [7], comparing different cell lines in terms of their
SNP genotype is unworkable, and so we developed instead a set of
isogenic breast epithelial cell line models to study the role played
by rs2981578 in mediating breast cancer risk. To this end, zinc
finger nuclease (ZFN) technology was used as a means of editing
rs2981578 in breast cancer cells. This system relies on homologous
recombination to create knock out and knock in models of genes in
both organisms and cell lines, to study the role of genes and/or
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Figure 1. Analysis and editing of intron two of FGFR2. A) Estimated relative risk of rs2981578 associated with breast cancer development, for
each possible genotype. Data from [3,4]. B) Copy number variation (CNV) at the FGFR2 locus in a panel of ERa positive (pink) and ERa negative (white)
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regulatory sequences. Random transgene integrations have the
principal drawback of unpredictable gene expression due to
multiple transgene copy integration and lack of control over
integration sites [8,9]. Site-specific recombination is much more
precise, but has relatively low efficiency. A key advantage of
targeted genome editing using ZFNs is that it leaves the
neighbouring DNA intact and is therefore a more suitable
approach for the study of regulatory DNA. Recently, ZFNs have
been used to drive efficient genome editing in rat zygotes [10],
human embryonic stem cells [11], human cancer cells [12] and
human T cells [13]. A recent study has attempted to modulate the
response to certain anti-cancer drugs by deleting polymorphisms
in the pro-apoptotic gene BIM, which affect the response to
tyrosine kinase inhibition [14].
In this study, ZFN technology was used as proof of concept to
engineer and study functional intronic SNPs. Site specific genome
editing was achieved using ZFN and homologous recombination,
resulting in a panel breast cancer cell lines composed of three
MCF7-derived clones heterozygous for rs2981578, and three
MCF7-derived wild-type controls that lack the disease associated
allele of the SNP.
Experimental Procedures
Cell Culture and Genomic DNA Isolation
The breast adenocarcinoma MCF7 cell line [15] and derived
clones were cultured in DMEM supplemented with L-Glutamine
and 10% foetal bovine serum (FBS), as were T47D, H3396, BT20,
MDA-MB-231, MDA-MB-453 and b4-1089 [16] cell lines.
MCF10A cells were cultured in DMEM:Ham’s F12 1:1 volume,
insulin from bovine pancreas (10 mg/ml), Hydrocortisone
(500 ng/ml), cholera enterotoxin (100 ng/ml), human EGF
(20 ng/ml) and 5% horse serum (all from Sigma). ZR-75-1 and
SKBR3 lines were cultured in RPMI medium (PAA laboratories)
supplemented with 10% FBS. MDA-MB-468 cells required L15
medium and 10% FBS. SUM159 cells were cultured in Ham’s F12
medium with 5% FBS, insulin (0.01 mg/ml) and hydrocortisone
(500 ng/ml).
Genomic DNA was purified from each cell line using the
GenEluteTM mammalian genomic DNA miniprep kit (Sigma)
according to the manufacturer’s instructions and the samples were
sequenced using a Big Dye Terminator kit (Applied Biosystems).
ERa Pathway Inhibition
Cells were seeded in 6 well plates at a density of 36105 cells per
well in normal medium. The cells were treated with 1 mM
Tamoxifen (Sigma) or with ethanol (vehicle control) for 48 hours
and total RNA was purified using an RNeasy Kit (Qiagen)
according to manufacturer’s recommendations. Complementary
DNA was generated from 500 ng of RNA and quantitative real
time PCR performed using SYBR Green (Invitrogen) and the
StepOnePlus Real-time PCR system (Applied Biosystems). The










Cells were seeded in 6 well plates at a density of 36105 cells per
well in normal medium. After 24 hours, medium was replaced
with starvation medium (DMEM +0.1% BSA). The following
morning, starved cells were stimulated from 5 min to 1 hour with
differing concentrations of ligand (100, 50, 10, 1 ng/ml of FGF7
or FGF10, Peprotech) and 300 ng/ml of Heparin (Sigma). At the
end of the treatment time point, the cells were lysed in 2X NuPage
Sample buffer (Invitrogen) supplemented with 10 mM DTT and
western blotting was performed using anti phospho-ERK
(#9101S, Cell Signalling) and anti-HSC70 antibodies (sc-7298,
Santa Cruz).
ER Positive Breast Tumours from Patients
Frozen tissue from ER positive breast tumours was obtained
from the Breast Cancer Campaign Tissue Bank (Barts Cancer
Institute, BCI), under ethical approval (Ethics REC reference: 10/
H0308/49) from the North East London ethics committee. Total
DNA from breast tissues was extracted using a GenEluteTM
mammalian genomic DNA miniprep kit (Sigma) (according to
manufacturer’s instructions) and total RNA was purified using
Trifast reagent (PeqLab). SNP genotyping of rs2981578,
rs1047100 and rs755793 was performed by Taqman SNP
genotyping assay (Applied Biosystems). Genotyping results were
visualized using the Genotyper software, version 1.0.1 (Applied
Biosystems), whereas specific allele amplification data could be
read using SDS software, version 2.3 (Applied Biosystems).
FGFR2 ZFN Pair
CompoZrTM custom made FGFR2 ZFNs were purchased from
Sigma. Messenger RNAs encoding the two ZFN modules were
generated from ZFN plasmids (linearised with XbaI) by run-off
transcription using a MessageMax T7 mRNA transcription kit
(Epicentre). The ZFNs were tested by transient transfection into
MCF7 cells, to test for disruption of the sequence of intron 2 of
FGFR2. Cutting efficiency at the target locus was determined by
Surveyor (Cel I) endonuclease-based measurement of non-
homologous end joining (NHEJ), as described [17,18] (primers
used in Cel I analysis: ZFN_For, 59- GCAGAGTTTCTTGC-
CAGGTC-39 and ZFN_rev, 59- ACATTCCACGTTAA-
GAGCCG-39). Analysis of off-target cleavage by ZFNs, which
results in NHEJ-mediated indels, was performed by sequencing
the top off-target hits as determined by the algorithm from the
ZFN site website (http://ccg.vital-it.ch/tagger/targetsearch.html).
The results are described in detail in Figure S1.
ZFN-mediated Genome Editing of MCF7 Cells
ZFN pairs were transfected into MCF7 cells using the Amaxa
System (Lonza). Nucleofection was performed using the Cell line
breast cancer cell lines. Data obtained from DNA copy number Affymetrix SNP 6.0 array, Cancer cell line Encyclopaedia (Broad Institute). The table
represents the rs2981578 genotype in a panel of breast cancer cell lines and their respective ER status and FGFR2 copy number (CN). C) The target site
of the FGFR2 ZFN pair. Genome editing was carried out at in the second intron of FGFR2, at the ZFN cutting site, 100 bp away from rs2981578. An
exogenous repair template was used for targeted homology repair and introduction of the risk allele in MCF7 cells. D) Surveyor Assay in MCF7 cells
after ZFN or GFP transient transfection. Post PCR DNA products were digested with Cel-I endonuclease to assess ZFN-mediated cleavage of the target
site. E) Sequencing trace of the rs2981578 locus (asterisk) showing the introduction of the risk allele (A;G) in the normally homozygous MCF7 cells
(A;A).
doi:10.1371/journal.pone.0078839.g001
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Figure 2. Functional impact of rs2981578 allelic modification in a panel of heterozygous and control MCF7 clones. A) Morphological
appearance of a control versus a heterozygous clone (Scale bar: 50 mm) and expression of ERa in control and heterozygous clones. HSC70 was used
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NucleofectorTM kit L (Lonza) using the programme P-020. A
repair template donor plasmid was constructed by cloning 2,154
base pairs of the FGFR2 intron, corresponding to
Chr10:123,339,177-123,341,331, surrounding the SNP (G allele)
at Chr10:123,340,311 (GRCh37/hg19), into pJet1.2 (VWR
International). 26106 cells were harvested with 10X Trypsin/
EDTA (GE Healthcare) and resuspended in 100 ml complemented
transfection solution, 2 mg of donor plasmid, 2 mg of pmaxGFP
(Lonza) and 2 mg of each ZFN mRNA. Immediately after
electroporation, 500 ml warm complete medium was added to
the cuvette and the cell suspension was transferred to a 100 mm
culture dish, with 10 ml warm complete medium. The medium
was changed 24 h post-Nucleofection. GFP enrichment, using an
ARIA II cell sorter (Becton Dickinson), was performed 48 hours
post transfection, which constitutes the peak expression window
for the pmaxGFP construct (Lonza). The cells were then seeded at
a concentration of 400 cells/plate, in 150 mm diameter culture
plates, and cultured for 14 days. Once the colonies reached
approximately 100 cells in size, the medium was removed and the
cells washed with sterile PBS. Individual colonies were picked and
transferred to a 96 well plate for clonal expansion.
FOXA1 Chromatin Immunoprecipitation
FOXA1 ChIP was carried as previously described [19] using
5 mg of anti-FOXA1 antibody (Ab5089, Abcam). Cells were plated
in a 150 mm culture dish. After 24 h, test cells were deprived of
oestrogen for 3 days by replacing the medium with phenol-red free
DMEM (Sigma) supplemented with 5% charcoal-stripped FBS
(Gibco). The starvation medium was changed every day for three
days. The starved cells were then stimulated with 100 nM of b-
oestradiol (Sigma) for 1 hour. The control plates were maintained
either in full medium or starved without oestrogen stimulation.
Real time quantitative PCR was used to assess the fold enrichment
of FOXA1 binding at the rs2981578 locus. Primers binding the
Greb1 promoter were used as a positive control and primers
recognising an intronic site of Cyclin D1 with no FOXA1 binding
site were used as negative control (CCND1_F, 59-TGCCACA-
CACCAGTGACTTT-39; CCND1_R, 59-ACAGCCA-
GAAGCTCCAAAAA-39). A master mix was prepared as
described previously and 2 ml of sample or input (1:14 dilution)
were added, in triplicate. The Ct values obtained were used to
evaluate the total amount of DNA in samples and inputs. The
enrichment was normalised first to the input and then to the
negative control.
Proliferation Assays
Cell viability, over a 72 h period, was measured by CellTiter 96
Aqueous One Solution Cell Proliferation assay (Promega). Cells
were seeded in 96 well plates at a concentration of 2,500 cells/
well, in triplicate for each time point (24 h, 48 h and 72 h). At the
end of each time point, the medium was removed and replaced
with 100 ml of fresh medium and 20 ml of CellTiter Solution. The
plate was incubated at 37uC for 2 h. Absorbance was measured at
490 nm on an LT-4000 Microplate reader (Labtech). Wells
without cells were used as blanks for normalisation.
For Ki67 staining, cells were plated on glass cover slips in 24
well plates at a density of 20,000 cells/well. The next day, cells
were fixed in 4% paraformaldehyde (PFA, Sigma) at room
temperature for 10 min and washed three times in PBS for 5 min.
Cells were permeabilised in 0.1% Saponin (Sigma) for 10 min,
followed by three PBS washes. Non-specific antibody binding was
blocked by incubation for 1 h in 5% BSA in PBS, prior to
incubation with anti-Ki67 antibody (FITC Mouse, 1:100 dilution,
BD Transduction). The cells were washed several times in PBS
with one last wash in distilled water, before mounting on a glass
slide with mounting medium (ProlongTM Gold DAPI antifade
reagent, Invitrogen). DAPI (49,6-diamidino-2-phenylindole), con-
tained in the mounting medium, allowed fluorescent labelling of
cell nuclei. Images were taken on a confocal laser-scanning
microscope LSM 510 (Zeiss). Quantification was performed by
counting the percentage of Ki67 positive cells per field of view,
under 40x objective (10 fields were analysed for each cell clone).
Cell Cycle Analysis
Cells at approximately 70% confluence were harvested by
trypsination, pelleted and resuspended in 1 ml of cold 70%
ethanol with vortexing. The cells were fixed at 4uC for 30 min
before being processed for staining with propidium iodide (PI,
Sigma). After two washes in PBS, the cells were resuspended in
350 ml of staining solution containing 50 mg/ml PI and 100 mg/ml
RNaseA (Sigma) diluted in PBS. The tubes were protected from
light and incubated at RT for 30 min.
The amount of DNA staining was assessed by flow cytometry
using a FACSCalibur machine (BD Biosciences). Raw data were
analysed using FlowJoTM software, using the Watson (Pragmatic)
algorithm. Two-way Anova statistical test was used to determine
significance (GraphPad Prism, version 5.03).
Selection Pressure Experiment
MCF7 cells (26106 cells) were transfected in triplicate with
mRNAs encoding the ZFN pairs, along with the MCF7 repair
template, as described earlier. At passage 1 post-nucleofection,
and every third passage thereafter, gDNA was extracted and used
for Taqman SNP genotyping assay to determine relative presence
of the major and minor allele of rs2981578 SNP over a period of
20 passages.
Allele Specific Expression
Specific SNP genotyping assays (rs2981578, rs1047100 and
rs755793, Applied Biosystems), using Taqman probes, were used
to discriminate between homozygous and heterozygous SNPs in
human breast tumour samples (using gDNA) and measure the
amount of relative allele expression (using cDNA). Allele specific
expression was measured in heterozygous samples only in order to
measure the absolute DCt between each allele.
as loading contol. Western blot is representative of three independent experiments. B) Quantitative RT-PCR of ERa expression level upon exposure to
1 mM Tamoxifen relative to control (vehicle, EtOH) for 48 h. C) Quantitative RT-PCR of PS2 and cMyb expression level, two target genes of ERa, upon
exposure to 1 mM Tamoxifen relative to control (vehicle, EtOH) for 48 h. mRNA levels are shown relative to GAPDH expression, and normalized over
untreated cells. Mean6 SEM of three independent experiments are presented. Two-way ANOVA showed no significant difference in expression levels
between the control and heterozygous clones (ERa: p = 0.6491; PS2: p = 0.1098; cMyb: p = 0.2304). D) Expression of FOXA1 in the controls and
heterozygous clones. HSC70 was used as loading control (western blot is representative of three independent experiments). FOXA1 ChIP in one
control and one heterozygous clone following exposure to oestrogen (E2) (full medium, E2 starvation or E2 stimulation). Primers recognizing the
rs2981578 locus and a positive control (Greb1 promoter) were used. ChIP was performed in triplicate and the amount of precipitated DNA were
normalized to the input DNA and a negative control (CCDN1 intron). Student’s two-tailed t-Test was used to analyse significance.
doi:10.1371/journal.pone.0078839.g002
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Figure 3. FGFR2 expression and signaling. A) Quantitative RT-PCR of FGFR2 isoforms (FGFR2a, FGFR2b and FGFR2c) in control and heterozygous
clones. Error bars represent SEM of three independent experiments. Two-way ANOVA showed no statistical significance in expression of the receptors
in control versus heterozygous clones. B) Representative western blots of ERK phosphorylation following stimulation of control and heterozygous
clones with 100 ng/ml FGF7 and FGF10. HSC70 is used as loading control. C) Representative western blots of ERK phosphorylation following
stimulation of the MCF7 clones with different amount of FGF7 and FGF10. HSC70 is used as loading control. The stimulations were performed in
triplicate.
doi:10.1371/journal.pone.0078839.g003
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Figure 4. Investigating allele-specific effects on cell proliferation. A) Cell cycle analysis by PI staining and flow cytometry. No statistical
differences were observed between the proportion of cells in each phase of the cell cycle between the control and the heterozygous clones (2-way
ZFN-Mediated Engineering of FGFR2 SNP
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Results
Cell Line Editing of the FGFR2 Breast Cancer Risk
Haplotype
Rs2981578 has three possible genotypes in diploid cells: (A;A),
(A;G) and (G;G), where the G allele is the disease associated allele
that confers an increased risk of developing ER positive breast
cancer (Fig. 1A). One copy of the risk allele confers a 1.2 fold
increase in risk for breast cancer development, and this figure
increases to 1.64 for individuals homozygous for the risk allele
(Fig. 1A) [4]. The SNP status of rs2981578 was investigated in
several candidate breast cancer cell lines. Cell lines were classified
dependent on their ERa status, since this was the only tumour
characteristic found to be associated with FGFR2 dependent risk,
and their respective FGFR2 copy number. Since many cultured
cancer cell lines are highly aneuploid, it was important to identify
lines that were diploid for chromosome 10, where FGFR2 is
located, in order to avoid having to target multiple FGFR2 alleles.
Copy number variation data from the Cancer Cell Line
Encyclopaedia (Affymetrix SNP6.0 Array, CCLE, Broad Institute)
were used to determine whether the candidate cell lines showed
FGFR2 deletion or amplification (Fig. 1B). All the cell lines
investigated were homozygous, A;A or G;G, except SKBR3. The
proportion of cell lines with the non-disease associated allele (four
out of eleven A;A) was slightly lower relatively to the disease-
associated allele (six out of eleven G;G). We hypothesised that the
putative phenotype of rs2981578 could be more visible in the early
stage of breast cancer development, rather than at a more
advanced stage, where other oncogenic mutations might mask any
phenotypes related to the SNP; therefore candidate cell lines that
represented relatively early stage breast cancer, with only two
copies of chromosome 10, were favoured. The MCF7 cell line,
which is ERa positive and homozygous for the major, non risk-
associated, allele of rs2981578, was chosen for ZFN-mediated
genome editing.
Genome editing with engineered ZFNs relies on induction of
targeted double-stranded break (DSB) by the nuclease heterodimer
and by targeting the DSB in close proximity to the genomic locus
of interest allows point mutations to be transferred with maximal
efficiency from a repair template. Our ZFN pair introduced a DSB
100 bp 39 to rs2981578 (Fig. 1C), located in the large second
intron of FGFR2. To confirm the cutting efficiency of the ZFN
pair, DNA from MCF7 cells transfected with mRNAs encoding
the ZFN pairs was isolated and screened by surveyor assay. The
success of ZFN targeting can be assessed directly by visualising the
Cel-1 mediated digestion of heteroduplex products, formed by
annealing wild type and ZFN targeted PCR products. This
demonstrated significant cutting efficiency at the FGFR2 locus
(Fig. 1D).
Since modification of the rs2981578 risk locus entailed an
extremely precise change, we designed a genome editing method
without a drug selection strategy, to avoid altering the DNA
sequence by anything more than the targeted SNP nucleotide
(Fig. 1C). An exogenous donor construct comprising 1 kb
homology on each side of the ZFN-targeted site and carrying
the risk allele (G) of rs2981578, together with the ZFN mRNAs
and pmaxGFP construct, were electroporated into MCF7 cells.
SNP genotyping Taqman assay for rs2981578 was used to analyse
72 resultant individual single-cell clones, of which 3 clones (Het 1–
3) were edited successfully and contained one de novo copy of the
risk allele of rs2981578 (4.1% monoallelic genome editing
efficiency), which was confirmed by sequencing (Fig. 1E). None
of the clones screened showed biallelic modification of rs2981578.
Three controls chosen from unmodified MCF7 clones (which were
subject to the same treatment as heterozygous clones), and three
heterozygous clones were selected for functional characterization.
All these clones are freely available from the Grose Lab.
Unfortunately, the generation of homozygous (G/G) clones
proved extremely challenging and was beyond the scope of this
study.
Oestrogen Receptor Signalling and FOXA1 Binding in
Heterozygous Clones
MCF7 cells are a weakly metastatic breast cancer cell line,
growing in clusters and retaining contact inhibition. At confluence,
they show cobblestone morphology, typical of epithelial cell lines.
There was no difference between heterozygous and control lines.
The appearance of the sub-lines varied moderately between each
other (Fig. 2A) but did not correlate with the rs2981578 genotype.
Since ER positivity constitutes the only significant tumour
characteristic that was associated with the FGFR2 SNP haplotype,
ERa expression levels in the MCF7 clones were determined.
Western blot analysis showed no significant difference in the levels
of ERa between the three heterozygous lines as compared to three
control lines (Fig. 2A). To test whether the acquisition of one copy
of the risk allele altered ER signalling in MCF7 clones, cells were
treated for 48 hours with Tamoxifen, an ER antagonist, and the
expression of ERa and two of its canonical target genes, PS2 and c-
Myb [20,21] was examined. Tamoxifen treatment led to a
significant increase in the levels of ERa mRNA in all clones,
when compared to the untreated cells (Fig. 2B). We observed a
significant reduction in the expression level of two of ERa target
genes (p,0.0001), which was equivalent in both control and
heterozygous clones. Since ER expression and responsiveness were
similar in all the clones, we concluded that rs2981578 SNP status
has no striking effect on ERa.
In a previous study, Runx2 was identified as the transcription
factor mediating the increase in FGFR2 expression in cell lines
with the disease associated allele of rs2981578 [5]. In vitro studies
showed that exogenous Runx2 was able to bind the promoter of a
Iuciferase reporter gene on a site containing multiple repeats of the
disease associated allele and its surrounding sequence. The disease
associated allele at the Oct1/Runx2 site stimulated transcription 2
to 5 fold over the non-disease associated allele, independently of
orientation. ChIP data were less conclusive and showed only a
relatively modest increase in Runx2 binding [5]. Our attempts to
replicate the Runx2 ChIP data for the rs2981578 locus in MCF7
cells heterozygous for the risk allele failed to show any significant
Runx2 binding at the SNP locus (data not shown). Therefore, we
ANOVA p=0.1293). Error bars represent SEM of three independent experiments. B) Ki67 staining of the fixed MCF7 clones was performed to assess
cell proliferation. Quantification was performed by counting the percentage of positive cells in 10 fields of view for each clone (on average 976 cells/
10 fields). Mean 6 SEM of three experiments are represented. One-way ANOVA showed no significant difference in proliferation between clones
(p = 0.3573). Scale bar = 50 mm. C) MTS assay comparing the cell number between control and heterozygous clones over a period of 72 hrs. Mean 6
SEM of three experiments are presented. D) Three independent cultures (ZFN1, ZFN2 and ZFN3) of wild-type MCF7 cells were transfected with ZFN
mRNA and the exogenous repair template (containing the risk allele) and kept in culture over a period of 20 passages. The amount of each allele of
rs2981578 was assessed every three passages using a specific SNP genotyping Taqman assay. The results are represented as Ct values for each allele
over time. Untransfected MCF7 cells were used as controls.
doi:10.1371/journal.pone.0078839.g004
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Figure 5. Assessment of ASE in breast cancer. A) Cartoon representing ASE where a cis-regulatory difference exists between G (blue) and A
(grey) alleles. The activity of allele G is higher because of the differential binding of a transcription factor (yellow), which results in a relative
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interrogated publicly available online whole-genome ChIP-seq
data, to identify other potential transcription factors capable of
binding at the rs2981578 locus. Data from MCF7 and HepG2 cell
lines revealed that the pioneer factor FOXA1 binds to DNA at this
locus. FoxA1 is responsible for opening condensed chromatin,
facilitating access by other transcription factors, and has been
shown to play an important role in maintaining euchromatic
conditions and to be required for ERa binding [19]. Thus FOXA1
constituted an ideal candidate for studying the link between
FGFR2 intronic SNPs and increased risk of ER-positive breast
cancer. The binding of FOXA1 to the rs2981578 SNP locus was
confirmed in MCF7, T47D and ZR75-1 cell lines by ChIP-seq
data analysis from a study on FOXA1 and ERa function in breast
cancer [22]. Since FOXA1 is capable of binding transcriptionally
inactive chromatin, MCF7 clones were either cultured in full
medium or starved of oestrogen for 4 days and stimulated (or not)
with 100 nM of b-oestradiol for 1 hour, prior to chromatin
isolation and ChIP analysis. Sites within the fourth intron of
CCND1 (Cyclin D1) and the Greb1 (growth regulation by oestrogen
in breast cancer 1) promoter were used as negative and positive
control, respectively, for FOXA1 binding [23]. As expected,
control cells showed enhanced binding of FOXA1 to the Greb1
promoter following oestrogen stimulation (additional 200 fold
FOXA1 enrichment versus input compared to starvation condi-
tions (p = 0.005)). Heterozygous cells showed relatively lower
enrichment of FOXA1 binding. Despite an unexpected high level
of FOXA1 binding to the Greb1 locus in heterozygous cells
growing in full serum, the cells still showed a positive response of
FOXA1 binding to the Greb1 promoter following oestrogen
stimulation (additional 14 fold FOXA1 enrichment versus input
compared to starvation conditions (p = 0.02), Fig. 2D). Control
clones (A;A) showed significantly enhanced FOXA1 binding at
rs2981578 relative to heterozygous clones (A;G) in all culture
conditions, but most notably following ERa stimulation
(p = 0.002). Total FOXA1 levels were equal in both control and
heterozygous cell lines (Fig. 2D).
FGFR Signalling in ZFN-modified Clones
Having determined that rs2981578 status may determine levels
of FOXA1 binding, we investigated FGFR2 receptor expression
and signalling in the control and heterozygous MCF7 clones. They
expressed all FGFR2 isoforms, predominantly the epithelial-
associated isoform FGFR2-b (Ct value = 32 for FGFR2b vs. 34–35
for FGFR2a and c). Real-time PCR showed no statistically
significant difference, in terms of isoform levels, between the
control and the heterozygous clones (Fig. 3A). Note that the three
isoforms are all expressed relative to GAPDH, but not to each
other. The same clones shown in figure 2E were used in cell-based
assays. Firstly, cells were stimulated with either 100 ng/ml FGF7
or FGF10, in the presence of heparin. Both FGF10 and FGF7
elicited robust ERK phosphorylation, sustained after 60 minutes of
stimulation in both control and heterozygous cells (Fig. 3B). The
sensitivity of the receptors to ligand concentration was also
assessed (Fig. 3C). Even the smallest amount of ligand (1 ng/ml)
elicited ERK phosphorylation, demonstrating no apparent change
in receptor affinity for the ligands. From these first observations,
the risk allele of rs2981578 did not affect directly the expression
level or the signalling of FGFR2.
Assessing Allele Specific Effects on Cell Proliferation
in vitro
In order to detect the impact of the single nucleotide change,
heterozygous MCF7 clones were compared to their control
counterparts in a series of in vitro assays. Firstly, the six clones
were subjected to cell cycle analysis using PI staining followed by
flow cytometry. The heterozygous clones displayed a normal cell
cycle profile, similar to the wild-type controls (Fig. 4A). All clones
showed reduced proliferation rate compared to MCF7 cells that
had not been subject to single cell cloning (data not shown). Anti-
Ki67 staining (Fig. 4B) and MTS assay (Fig. 4C) did not reveal any
significant differences in proliferation between the clones. The
process of single cell cloning did not affect the proliferative
capacity of MCF7 cells (data not shown).
In order to test whether SNP genotype may influence the
proliferation rate of cells that had not undergone single cell
cloning, three separate flasks of MCF7 cells were transfected with
ZFN mRNA risk allele repair template, and maintained as a
polyclonal population. The three heterogeneous populations
(ZFN1, ZFN2, ZFN3), composed of a mixture of wild-type
MCF7 (A;A) and ZFN-modified cells (A;G or G;G), were cultured
over a period of 20 passages. The relative frequency of each
rs2981578 allele was measured over time using allele-specific
Taqman probes to monitor any changes in the proportion of the
two different genotypes.
The Ct values revealed, as expected after ZFN genome editing,
a predominance of wild-type cells (with Ct values around 30
cycles), with a slight increase (2 cycles difference) in G allele
frequency post ZFN transfection, that persisted for 3 passages
(Fig. 4D). However, the Ct values returned to the level of the
control, untransfected cells rapidly and no additional changes in
Ct values were observed. The apparent increase in G allele
frequency at passage 17 was an artifact caused by the poor quality
of the genomic DNA samples, as this drop in Ct values was
observed for both G and A alleles. Thus the presence of the G
allele in the FGFR2 haplotype did not give a measurable growth
advantage to rs2981578 modified MCF7 cells in 2D culture.
FGFR2 Allele Specific Expression in a Panel of Breast
Cancer Samples
Using the relative expression levels of variant SNP alleles within
the coding region of a gene in the same sample (instead of using
total mRNA levels originating from the two different copies of a
gene) is an effective approach for identifying cis-acting regulatory
SNPs [24]. Since rs2981578 is intronic, and therefore spliced out
of mature mRNA, the allelic origin of each mRNA molecule was
tracked by looking at additional heterozygous marker SNPs in the
coding region (Fig. 5A).
Potential marker SNPs located in the coding region of FGFR2
were identified using the Ensembl Genome Browser website [25],
by looking at the single nucleotide variants observed in the
different FGFR2 transcripts. Among 327 total variations found in
the coding sequence, 148 were synonymous variants and 179 were
non-synonymous. Two of those variants were shortlisted, since
abundance of blue mRNA transcript. A marker SNP, located in the coding region of the gene and with a heterozygous genotype, is used to
differentiate the origin of each mRNA transcript synthesized (C and U). B) Allele frequencies for rs2981578 and two marker SNPs measured in a panel
of 72 ERa positive breast cancer samples. C) Absolute DCt was measured in five samples that were heterozygous both for rs2981578 and rs1047100
(marker SNP) and compared to 11 controls in which rs2981578 was homozygous. Mann Whitney test revealed no statistical differences between the
two groups.
doi:10.1371/journal.pone.0078839.g005
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they showed minor allele frequencies greater than 10%. The
essential characteristic of a marker SNP is its heterozygosity, thus
minor allele frequency is an important factor because the greater
the minor allele frequency, the better the chance of identifying
heterozygous samples within cell lines or patient tissue samples.
SNP rs1047100 was identified as a synonymous SNP located in
exon six of FGFR2 (GTA/GTG). This nucleotide variance at
position Chr10:123298158 (GRCh37) encodes for valine in both
cases. The minor allele (A) frequency varies between 8% to 22% in
the different populations of the 1000 Genomes project [26]. The
second marker was the non-synonymous SNP rs755793 (ATG/
ACG) in exon five, Chr10:123310871 (GRCh37). The ancestral
codon, containing the thymine nucleotide, encodes for a
methionine, substituted for threonine in the presence of the C
allele. The minor allele (C) frequency varies greatly between
populations, with a 36% frequency in African populations and an
absence in European populations. Therefore, SNP rs1047100 was
used predominantly in this study to determine the allelic origin of
the FGFR2 mRNA molecules, because of the more homogeneous
allele frequencies across populations and the fact that this change
does not affect the amino acid sequence of the protein translated
from the mRNA transcript.
Given the established limitation of using cell lines (too few in
number and not carrying the adequate genotypes) (Fig. 1C), tissues
from patients with ERa positive breast cancer were interrogated.
Breast tissue samples were obtained from the Breast Tissue Bank
at Barts in collaboration with Prof Louise Jones (ethics approved
ref no. 05/Q0403/199) and selected purely on the basis of ERa
positivity, regardless of treatment and ethnicity (figure S2). DNA
and RNA from 72 ERa positive breast tumours and their
surrounding tissues were used and each sample was genotyped for
rs2981578 and the two marker SNPs (Fig. 5B). The allele
frequencies of rs2981578 and rs1047100 in the patient samples
were representative of the overall population data from the 1000
Genomes project (data not shown). Allele G of rs755793 was
represented at a frequency higher than predicted from population
data, indicating a potential bias towards an increased number of
patients with African descent in the sample set. However, only
8.3% of the patients were of a Black background compared to
68% of a White background. Additionally, patients qualified as
Asian in the sample set (composed of Indian, Bangladeshi and
Pakistani patients) represented 10% of the samples and were not
representative of the East Asian population (ASN) of the HapMap
or the 1000 genomes data bases, composed mostly of Chinese,
Japanese and Vietnamese individuals. Little information is
available as yet on SNP allele frequencies in Indian, Bangladeshi
and Pakistani populations (SAN, south Asian super population
code).
Five samples, which were heterozygous for both functional and
marker SNPs, were selected for ASE analysis (Fig. 5C). Real time
PCR using allele-specific Taqman probes was performed for each
sample, using complementary DNA (cDNA) templates. Imbal-
anced allelic expression is detected when the heterozygous allele
ratio in mRNA (cDNA) differs from the normal allelic ratio of 1:1.
Cycle threshold (Ct) values obtained for both alleles of rs1047100
in cDNA were subtracted to obtain the absolute differences
between Ct values (DCt) (Fig. 5C). Mann Whitney test indicated
that the results did not show significant difference in absolute levels
of expression (i.e. allelic imbalance) in the heterozygous samples
compared to controls (p = 0.1645)(A;A and G;G genotypes).
Discussion
GWAS have shown that the SNP haplotype in intron two of
FGFR2 is an important risk locus for the development of breast
cancer [3,4], but they do not address the mechanisms underlying
risk association. We have used a novel genome editing approach to
address the translational relevance of these data.
Conventional methods for the study of gene function can be
challenging when looking at non-coding DNA regulatory
sequences. Commonly, indirect methods such as Luciferase assay
are used, but do not include all the cellular factors that might
influence gene expression regulation (eg. endogenous trans-acting
factors, epigenetic marks, chromosome conformation). ZFN-
mediated genome editing presents several advantages over
conventional methods as it can generate isogenic cell lines in
which modifications at the endogenous genomic DNA sequence
have been introduced without any additional changes in the DNA
sequence. The biological variability associated with the use of
different human cancer cell lines might thereby be abrogated and
the study of single polymorphisms in identical genetic context
made possible. Here we show that ZFN genome editing can be
used in the study of cancer polymorphism risk factors.
We obtained three MCF7 clones carrying one copy of the
rs2981578 risk allele (none had a biallelic change) and three other
non-modified clones were selected as controls. The potential off-
target effects of the FGFR2 ZFN pair were evaluated by
sequencing of the top seven putative off-target binding sites, and
no deletions due to NHEJ were observed in any of the clones.
There were no discernible SNP dependant differences in the
appearance of any of the MCF7 clones, although the cell lines did
vary. It has often been reported that MCF7 cells, like many cell
lines [27] have a tendency to deviate from their initial phenotypes
as the number of passages in culture increases, and discrepancies
in phenotypic appearance may also have been exacerbated by the
stress of single cell cloning.
FGFR2 has been reported to act as an oncogene in breast cancer
and increased FGF signalling might promote cancer initiation or
progression by protecting the cells from apoptosis [28] and
stimulating growth and proliferation [29]. Cell-based assays
showed that there was no change in cell cycle progression, nor
any apparent advantage in cell growth in cells carrying the risk
allele of rs2981578 (heterozygous versus non-modified controls).
Crucially, it was established that Runx2 was not the key
transcription factor mediating the rs2981578 risk, but instead,
the pioneer factor FOXA1 appears more important. FOXA1
ChIP showed a reduced binding of FOXA1 to the SNP locus in
two out of three of the heterozygous clones, whereas a very strong
binding was observed in two out of three control cell lines. FOXA1
is crucial in mediating the binding of ERa to its target genes, and
whole genome ChIP-seq screening has demonstrated that FOXA1
plays a role in the reprogramming of ERa binding sites during
breast cancer progression [23,30]. Interestingly, Ross-Innes and
colleagues (2012) have shown that ERa binding is a dynamic
process and that new ERa-binding sites were unique to seven
patients with poor outcome as compared to eight patients with
good outcome. When using the ChIP-seq data from that study,
ERa was bound a few hundred base pairs away from the
rs2981578 locus and only in samples associated with poor
outcome. The current hypothesis regarding the role of FOXA1
in breast cancer is that FOXA1 is capable of mediating a
reprogramming of the ERa binding site [23]. The role of each
individual SNP forming the FGFR2 haplotype, or their collective
effect, on the dynamics of FOXA1 binding at the FGFR2 locus
remains to be elucidated.
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The cohort of 72 patient samples did not show any allelic
imbalance in FGFR2 expression. However, the heterogeneous
nature of the tumour samples used might explain the lack of allelic
imbalance if ASE is cell type specific. Indeed, published data
suggest that the rs2981578-associated risk is cell type-dependent,
and that the increased FGFR2 signaling and resulting oncogenic
phenotype was only observed in stromal fibroblasts and not in cells
of epithelial origin, like the MCF7 cell line [31]. It was also
reported that the phenomenon of ASE is not present in 100% of
heterozygous individuals and that other heritable factors might
determine whether or not an allele is differentially expressed,
indicating that an increased cohort of patients would be required
to gain more statistical power to determine ASE [32]. Interest-
ingly, the ethnic composition of our patient cohort has revealed
that genetic data on population originating from central and
western Asia, such as India, Bangladesh and Pakistan, are
currently missing from the main publicly available databases such
as the 1000 Genomes project (Figure S2).
Several limitations were encountered during the genome editing
process, limiting the number of clones available for screening. One
of the major obstacles was choice of potential ZFN binding sites
for the SNP editing. The ZFN target sequence had to be restricted
to the immediate vicinity of the target SNP, which meant that the
optimal ZFN pair was less efficient than if the whole FGFR2 locus
been available for targeting. The problem of relative low efficiency
of gene editing is common to many other studies and a lot of
efforts are now being put into improving ZFN technology, as
exemplified by recent reports suggesting the use of the proteasome
inhibitor MG132 during the editing process as a way to increase
the half-life of ZFN proteins [33], or the use of surrogate reporters
that express GFP only when the reporter has been cleaved by the
ZFN and a consequent frame shift mutation has occurred [34].
Taken together, we have shown that, while the SNP status of a
cell line can be engineered specifically at the nucleotide level, in
the case of rs2981578, this has no clear effect on cell phenotype.
To complement our in vitro studies, we have analysed a panel of
clinical samples for ASE, but again there is no clear evidence for
rs2981578 status impacting of FGFR2 expression. Since the data
implicating the FGFR2 intron 2 haplotype in breast cancer are
clear, from many independent studies, we hypothesise that there
must be alternative SNPs impacting on cell behaviour.
Supporting Information
Figure S1 Assessment of FGFR2 ZFN off-target effect. A)
Potential off target sites as determined from the ZFN site website
(http://ccg.vital-it.ch/tagger/targetsearch.html). When a nucleo-
tide mismatch is found at a given position between query and hit,
the mismatched position is highlighted and underlined; the
original nucleotide being displayed underneath (red). The spacer
sequence size is represented by Ns (green). Results also show the
number of mismatches between queries and mismatch site, and
the genomic locus of the putative off-target site. B) Sequencing
results of the off-target ZFN binding site for each clone. A tick
means that the sequence was identical to the Ensembl database,
proving that the ZFN did not cut that locus. N.A. refers to a
sequencing reaction that failed to give readable sequencing trace.
(TIF)
Figure S2 Ethnicity of breast cancer samples. Proportion
of each ethnicity within the 72 breast cancer samples obtained
from the Barts Breast Tissue Bank.
(TIF)
Acknowledgments
We are grateful to Professor Denise Sheer and Dr Kerstin Meyer for advice
and technical guidance.
Author Contributions
Conceived and designed the experiments: LJRM CB JLJ HCH JF IRH
RPG. Performed the experiments: LJRM CB RPG. Analyzed the data:
LJRM CB JLJ HCH JF IRH RPG. Contributed reagents/materials/
analysis tools: LJRM CB JLJ HCH JF RPG. Wrote the paper: LJRM
RPG.
References
1. Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence,
mortality, and prevalence across five continents: defining priorities to reduce
cancer disparities in different geographic regions of the world. J Clin Oncol 24:
2137–2150.
2. Motulsky AG (2006) Genetics of complex diseases. J Zhejiang Univ Sci B 7: 167–
168.
3. Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, et al. (2007) A genome-
wide association study identifies alleles in FGFR2 associated with risk of sporadic
postmenopausal breast cancer. Nat Genet 39: 870–874.
4. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, et al. (2007)
Genome-wide association study identifies novel breast cancer susceptibility loci.
Nature 447: 1087–1093.
5. Meyer KB, Maia AT, O’Reilly M, Teschendorff AE, Chin SF, et al. (2008)
Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer.
PLoS Biol 6: e108.
6. Turner N, Grose R (2010) Fibroblast growth factor signalling: from development
to cancer. Nat Rev Cancer 10: 116–129.
7. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, et al. (2006) A collection of
breast cancer cell lines for the study of functionally distinct cancer subtypes.
Cancer Cell 10: 515–527.
8. Dellaire G, Chartrand P (1998) Direct evidence that transgene integration is
random in murine cells, implying that naturally occurring double-strand breaks
may be distributed similarly within the genome. Radiat Res 149: 325–329.
9. Conner AJ, Jacobs JM (1999) Genetic engineering of crops as potential source of
genetic hazard in the human diet. Mutat Res 443: 223–234.
10. Geurts AM, Cost GJ, Freyvert Y, Zeitler B, Miller JC, et al. (2009) Knockout
rats via embryo microinjection of zinc-finger nucleases. Science 325: 433.
11. Chang CJ, Bouhassira EE (2012) Zinc-finger nuclease-mediated correction of
alpha-thalassemia in iPS cells. Blood 120: 3906–3914.
12. Gutschner T, Hammerle M, Eissmann M, Hsu J, Kim Y, et al. (2012) The non-
coding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung
cancer cells. Cancer Res.
13. Wilen CB, Wang J, Tilton JC, Miller JC, Kim KA, et al. (2011) Engineering
HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleases.
PLoS Pathog 7: e1002020.
14. Ng KP, Hillmer AM, Chuah CT, Juan WC, Ko TK, et al. (2012) A common
BIM deletion polymorphism mediates intrinsic resistance and inferior responses
to tyrosine kinase inhibitors in cancer. Nat Med 18: 521–528.
15. Soule HD, Vazguez J, Long A, Albert S, Brennan M (1973) A human cell line
from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 51:
1409–1416.
16. Allen M, Mulligan K, Clark S, Hart I, Marshall J, et al. (2008) De novo
expression of avb6 integrin by myoepithelial cells in ductal carcinoma in situ
may be an important marker of disease progression. Breast Cancer Research 10:
28.
17. Miller JC, Holmes MC, Wang J, Guschin DY, Lee YL, et al. (2007) An
improved zinc-finger nuclease architecture for highly specific genome editing.
Nat Biotechnol 25: 778–785.
18. Perez EE, Wang J, Miller JC, Jouvenot Y, Kim KA, et al. (2008) Establishment
of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger
nucleases. Nat Biotechnol 26: 808–816.
19. Carroll JS, Liu XS, Brodsky AS, Li W, Meyer CA, et al. (2005) Chromosome-
wide mapping of estrogen receptor binding reveals long-range regulation
requiring the forkhead protein FoxA1. Cell 122: 33–43.
20. Gudas JM, Klein RC, Oka M, Cowan KH (1995) Posttranscriptional regulation
of the c-myb proto-oncogene in estrogen receptor-positive breast cancer cells.
Clin Cancer Res 1: 235–243.
21. Kim J, Petz LN, Ziegler YS, Wood JR, Potthoff SJ, et al. (2000) Regulation of
the estrogen-responsive pS2 gene in MCF-7 human breast cancer cells. J Steroid
Biochem Mol Biol 74: 157–168.
22. Hurtado A, Holmes KA, Ross-Innes CS, Schmidt D, Carroll JS (2010) FOXA1
is a key determinant of estrogen receptor function and endocrine response. Nat
Genet 43: 27–33.
ZFN-Mediated Engineering of FGFR2 SNP
PLOS ONE | www.plosone.org 12 November 2013 | Volume 8 | Issue 11 | e78839
23. Ross-Innes CS, Stark R, Teschendorff AE, Holmes KA, Ali HR, et al. (2012)
Differential oestrogen receptor binding is associated with clinical outcome in
breast cancer. Nature 481: 389–393.
24. Milani L, Gupta M, Andersen M, Dhar S, Fryknas M, et al. (2007) Allelic
imbalance in gene expression as a guide to cis-acting regulatory single nucleotide
polymorphisms in cancer cells. Nucleic Acids Res 35: e34.
25. Ensembl (2010) FGFR2 variation, Ensembl Genome Browser website.
26. Genomes (2011) The 1000 Genomes project, minor allele frequencies in
different populations.
27. Wenger SL, Senft JR, Sargent LM, Bamezai R, Bairwa N, et al. (2004)
Comparison of established cell lines at different passages by karyotype and
comparative genomic hybridization. Biosci Rep 24: 631–639.
28. Hishikawa Y, Tamaru N, Ejima K, Hayashi T, Koji T (2004) Expression of
keratinocyte growth factor and its receptor in human breast cancer: its inhibitory
role in the induction of apoptosis possibly through the overexpression of Bcl-2.
Arch Histol Cytol 67: 455–464.
29. Turner N, Lambros MB, Horlings HM, Pearson A, Sharpe R, et al. (2010)
Integrative molecular profiling of triple negative breast cancers identifies
amplicon drivers and potential therapeutic targets. Oncogene 29: 2013–2023.
30. Cowper-Sal lari R, Zhang X, Wright JB, Bailey SD, Cole MD, et al. (2012)
Breast cancer risk-associated SNPs modulate the affinity of chromatin for
FOXA1 and alter gene expression. Nat Genet 44: 1191–1198.
31. Huijts PE, van Dongen M, de Goeij MC, van Moolenbroek AJ, Blanken F, et al.
(2011) Allele-specific regulation of FGFR2 expression is cell type-dependent and
may increase breast cancer risk through a paracrine stimulus involving FGF10.
Breast Cancer Res 13: R72.
32. Yan H, Yuan W, Velculescu VE, Vogelstein B, Kinzler KW (2002) Allelic
variation in human gene expression. Science 297: 1143.
33. Ramakrishna S, Kim YH, Kim H (2013) Stability of Zinc Finger Nuclease
Protein Is Enhanced by the Proteasome Inhibitor MG132. PLoS One 8: e54282.
34. Kim H, Um E, Cho SR, Jung C, Kim H, et al. (2011) Surrogate reporters for
enrichment of cells with nuclease-induced mutations. Nat Methods 8: 941–943.
ZFN-Mediated Engineering of FGFR2 SNP
PLOS ONE | www.plosone.org 13 November 2013 | Volume 8 | Issue 11 | e78839
